Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;29(6):623-634.
doi: 10.1002/pds.5014. Epub 2020 May 3.

Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy

Joanne Salas  1   2 , John E Morley  3 , Jeffrey F Scherrer  1   2 , James S Floyd  4   5   6 , Susan A Farr  3   7 , Max Zubatsky  1 , Doug Barthold  8 , Sascha Dublin  6   9
Affiliations

Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy

Joanne Salas et al. Pharmacoepidemiol Drug Saf. 2020 Jun.

Abstract

Purpose: Emerging evidence suggests metformin compared with sulfonylurea is associated with an 8% to 10% lower risk for dementia. Guidelines recommend metformin as initial diabetes treatment, but there is still the question of treatment timing. Thus, the risk of dementia associated with initiating metformin compared with not initiating or delaying treatment was examined.

Methods: A retrospective cohort study (1996 to 2015) was conducted with electronic health records from Veteran Health Affairs (VHA; n = 112 845) and Kaiser Permanente Washington (KPW; n = 14 333) healthcare systems. Patients were aged ≥50 years, had a hemoglobin A1c (HbA1c) between 6.5 and <9.5 mg/dL, and did not have dementia or fills for antidiabetic medications before cohort entry. Initiators started metformin monotherapy and noninitiators used no antidiabetic medications in the 6 months after the first qualifying HbA1c. The primary outcome was incident dementia. Propensity scores and inverse probability of treatment weighting (IPTW) controlled for confounding in Cox proportional hazards models.

Results: During a median follow-up of 6.2 years in VHA and 6.8 years in KPW, there were 7547 new dementia cases in VHA and 1090 in KPW. After IPTW, there was no association between initiation of metformin (vs no initial treatment) and incident dementia in VHA (HR = 1.04; 95% confidence interval [CI]: 0.95-1.13) or KPW (HR = 0.81; 95% CI: 0.51-1.28). Results did not differ by age, baseline HbA1c, or race.

Conclusions: Results do not support initiating metformin earlier to prevent cognitive decline and, thus, may dampen enthusiasm for metformin as a potential antidementia drug. Randomized clinical trials could help clarify the relationship between metformin and cognitive decline.

Keywords: dementia; diabetes; metformin; pharmacoepidemiology.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interests and financial disclosures: Dr. Floyd has consulted for Shionogi Inc.

Figures

Figure 1.
Figure 1.
Veterans Health Administration eligibility criteria
Figure 2.
Figure 2.
Kaiser Permanente Washington State eligibility criteria
See this image and copyright information in PMC

References

    1. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4(6):640–650. - PMC - PubMed
    1. Chen F, Dong RR, Zhong KL, et al.Antidiabetic drugs restore abnormal transport of amyloid-beta across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology. 2016;101:123–136. - PubMed
    1. Kickstein E, Krauss S, Thornhill P, et al.Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A. 2010;107(50):21830–21835. - PMC - PubMed
    1. Mousavi SM, Niazmand S, Hosseini M, et al.Beneficial Effects of Teucrium polium and Metformin on Diabetes-Induced Memory Impairments and Brain Tissue Oxidative Damage in Rats. Int J Alzheimers Dis. 2015;2015:493729. - PMC - PubMed
    1. Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Front Endocrinol (Lausanne). 2018;9:400. - PMC - PubMed

Publication types

MeSH terms